Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 98.50
Bid: 97.00
Ask: 100.00
Change: 0.50 (0.51%)
Spread: 3.00 (3.093%)
Open: 98.00
High: 98.50
Low: 98.00
Prev. Close: 98.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Bidstack names new COO; Fintel expands deal

Thu, 13th Oct 2022 21:17

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Bidstack Group PLC - London-based in-game advertising platform - Appoints Camila Franklin as chief operating officer. She is replacing Lisa Hau who will move on to be the company's chief strategy officer. Franklin was previously COO at the gaming monetisation platform AdColony Inc.

----------

Hamak Gold Ltd - British Virgin Islands-based gold exploration firm focused on Liberia - Signs a contract with Cestos Drilling Liberia for an initial drilling programme to identify the depth and width extensions of significant gold mineralization. "We will shortly commence a drilling programme to test the width and depth extensions of the significant gold mineralization identified by soil and channel sampling over the Ziatoyah outcrop in our Nimba licence. We are pleased to be working with Cestos who have agreed to accept equity for the majority of their drilling services, showing their confidence in our programme and helping to conserve cash for the company in these challenging equity markets," Executive Director Karl Smithson comments.

----------

Amigo Holdings PLC - Bournemouth, England-based guarantor loan provider - Gets approval from the Financial Conduct Authority to return to lending with immediate effect. Notes that this is under "certain agreed conditions." Under the terms, it will undertake further customer outcomes testing, led by a third party, during the initial two-month pilot lending phase and a required period for assessment. If the FCA is satisfied with the outcome of this pilot phase, it will still be limited to a maximum of GBP35 million cumulative net originations until a further minimum GBP15 million scheme contribution from the proposed capital raise is paid into the scheme fund, it says.

----------

Arbuthnot Banking Group PLC - London-based bank - Notes its subsidiary, Arbuthnot Latham & Co Ltd, completed the sale of its long leasehold West End office property, 20 King Street, following the satisfaction of conditions.

----------

Fintel PLC - Huddersfield, England-based technology and support for retail financial services sector - Expands its strategic distribution partnership with Schroders PLC. Says Schroders will join Fintel's Risk Controlled investment solution. "Schroders and Fintel have worked closely together for a number of years and I am delighted that they have chosen to further strengthen this relationship by joining our Risk Controlled range. Fintel exists to help the market operate more effectively and with the continued success of the Managed Distribution and Risk Controlled we continue to deliver the technology and insight-led solutions the industry needs to ensure better consumer outcomes," Joint Chief Executive Matt Timmins comments.

----------

Minoan Group PLC - Surrey-based Greek hotel investor - Appoints Marco Nijhof to its board effective immediately. Says he is a board-level executive within the international luxury hotel and retail hospitality industry. "The appointment of Marco today is one of the final keys to reaching the commercialisation stages of the project. His experience in developing, commercialising and operating world-class tourism and other businesses will be crucial in the coming months as we near crystallisation of the project with the attendant increase in shareholder value," Chair George Mergos comments.

----------

Silverwood Brands PLC - London-based investing company targeting food, organic food, wellness, lifestyle and leisure sectors - Raises gross proceeds of GBP2.0 million through a subscription for new ordinary shares at an issue price of 40 pence per share. Records total income of GBP831,415 in the year to August 31. Net loss total GBP299,103.

----------

Artemis Resources Ltd - Perth-based miner with gold, copper and cobalt projects in Australia - Says the Greater Carlow project is a "high-grade gold copper-cobalt project primed for further growth". Says its resource compares very favourably to other gold mining projects on a grade equivalent basis. "What we have now established at the Greater Carlow project is a robust, credible, high-grade multi-metal resource from which our exploration team can now seek to continue to grow via drilling. The next phase at Greater Carlow is to drill and add more high-grade tonnes to the open pit and underground resources, including the high-grade Keel Zone which is not included in this resource statement," Executive Director Alastair Clayton comments.

----------

Cobra Resources PLC - Wudinna gold project in South Australia - Starts reverse circulation drilling at the Clarke prospect of its Wudinna gold project. This drilling will inform an updated gold mineral resource estimate and a maiden rare earth mineral resource estimate, it says.

----------

Firing Strategic Minerals PLC - operator of Atex dual lithium-tantalum project in Ivory Coast - Drills a total of 19 holes and completes 3,039 meters of drilling. It intersects pegmatite in all 19 drill holes. "I am pleased to provide our next update regarding our phase 1 core drilling programme, which has been completed successfully ... Lithium mineralisation was visually observed in eighteen out of the 19 holes, and we are now eagerly awaiting the assay results, the first of which should arrive during the fourth quarter of 2022," Chief Executive Yuval Cohen says.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Proposes a private placement to raise around EUR8 million through an accelerated book building. Plans to use the net proceeds of the placing would be used for the acceleration of the bexmarilimab clinical development programme and manufacturing. Total cash and cash equivalents held by the company as of June 30 amounted to EUR9.9 million.

----------

CleanTech Lithium PLC - Jersey-based lithium exploration and development company focused on Chile - Starts direct lithium extraction process work at its sustainable lithium projects in Chile. "We are delighted to move forward our process test-work with SunResin on multiple fronts including trials on brine from the sub-surface aquifers of our Laguna Verde and Francisco Basin projects, ordering of a DLE demo unit which will arrive in Chile this month and receiving a proposal for the DLE unit for a pilot plant that will produce battery grade lithium carbonate and lithium hydroxide for customer testing and verification," Chief Executive Aldo Boitano comments.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
12 Jul 2019 10:20

Faron Pharma Pleased By MATINS Progress And Plans To Increase Capacity

(Alliance News) - Faron Pharmaceuticals Oy said on Friday its MATINS study of nine cancer patients is progressing well, and it is planning to expand the clinical trial to more countries.The

Read more
26 Jun 2019 11:52

Faron Pharmaceuticals Says Traumakine Study Hindered By Steroid Use

(Alliance News) - Faron Pharmaceuticals Oy on Wednesday said interim results from its phase two Inforaaa study support continuation but the study is limited by a lack of patients not also taking a

Read more
14 Jun 2019 11:54

Faron Pharmaceuticals' Analysis Explains "Disappointing" Prior Trial

(Alliance News) - Faron Pharmaceuticals Oy on Friday said analysis of a more recent trial of Traumakine has explained why the drug did not perform as expected in a previous trial.Shares in

Read more
14 Jun 2019 10:37

Faron Pharmaceuticals reports 'significant' findings from YODA study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced results from its pharmacokinetic/dynamic 'YODA' study examining the administration of concomitant steroids and Traumakine in healthy volunteers on Friday.

Read more
24 May 2019 13:34

Faron Pharma Finance Head Wichmann Steps Down, Hanninen Replaces

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Friday said it has made several managerial changes, which it believes will strengthen its operating performance.The clinical stage said

Read more
24 May 2019 11:50

Faron appoints new CFO after some internal shuffling

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals updated the market on its board and management team on Friday, announcing that Yrjö Wichmann was leaving his current role as its chief financial officer to take up the new position of vice-president, financing and investor relations.

Read more
14 May 2019 14:16

Faron Pharmaceuticals Raises EUR1.3 Million Via Share Subscription (ALLISS)

LONDON (Alliance News) - Biopharmaceutical company Faron Pharmaceuticals Ltd said Tuesday that it has raised EUR1.3 million via share subscription.The company has issued 1.8 million shares

Read more
7 May 2019 11:44

Faron Pharmaceuticals Narrows Loss On Reduced Clinical Trial Costs

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Tuesday reported a slightly narrowed annual loss as the drug developer's research & development costs fell.Faron is a clinical

Read more
2 May 2019 17:30

Faron Pharmaceuticals Knows Of No Reason For 43% Share Price Jump

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it is unable to explain the recent movement in its share price.Faron noted Thursday's 43% share price rise, and said

Read more
30 Apr 2019 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 1 May J SainsburyFull Year ResultsConnect GroupHalf Year GroupQ1 Stock

Read more
29 Apr 2019 15:46

Faron Gets Results Of Traumakine Study From Japanese Licensing Partner

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said its Japanese licensing partner Maruishi Pharmaceutical Co Ltd has provided clinical trial results on its phase three Traumakine for

Read more
11 Apr 2019 12:13

Faron Pharmaceuticals To Focus On Colorectal Cancer In Clevegen Trial

LONDON (Alliance News) - Faron Pharmaceuticals Oy is to target colorectal cancer in its upcoming test programme for Clevegen, it said Thursday.The testing of Clevegen on patients with will

Read more
11 Apr 2019 11:22

Faron Pharmaceuticals upbeat on latest info from MATINS trial

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Thursday that the cohort expansion part of its phase 1 and 2 'MATINS' clinical trial, investigating the safety and efficacy of its wholly-owned novel precision cancer immunotherapy 'Clevegen', would begin with patients suffering from late-stage colorectal cancer as soon as the optimal dosing was determined.

Read more
26 Mar 2019 15:52

UPDATE: Faron Pharmaceuticals Raises EUR3.1 Million In Fundraise (ALLISS)

LONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday afternoon said it has raised EUR3.1 million pursuant to a placing announced earlier in the day.The company issued

Read more
26 Mar 2019 12:05

Faron Pharmaceuticals Optimistic For Traumakine As It Plans Fundraise (ALLISS)

LONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday said it expects further disappointing results from Traumakine, as it plans a share placing.Faron is currently for

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.